Table 1_Effectiveness of transcutaneous electrical acupoint stimulation for postoperative nausea, vomiting and pain in cancer patients: a systematic review and meta-analysis of randomized controlled trials.docx

ObjectiveTo evaluate the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) in relieving postoperative pain and reducing the incidence of postoperative nausea and vomiting (PONV) in patients undergoing cancer surgery.
MethodsA systematic search was conducted in PubMed, Web of Science, Embase, the Cochrane Library, CNKI, and Wanfang databases to identify randomized controlled trials (RCTs) published between January 2015 and May 2025. Postoperative pain scores at different time points, assessed using the visual analog scale (VAS) or numerical rating scale (NRS), as well as the incidence of PONV, postoperative nausea (PON), and postoperative vomiting (POV), were extracted. Subgroup analyses were performed according to the timing of TEAS intervention and pain assessment methods. The risk of bias was evaluated using the Cochrane Risk of Bias (RoB) tool, and the meta-analysis was conducted using RevMan 5.4 software.
ResultsA total of 16 randomized controlled trials involving 2,017 postoperative cancer patients were included (1,125 in the TEAS group and 892 in the control group). Meta-analysis of 13 studies showed that TEAS significantly reduced postoperative pain scores (SMD = −1.19, 95% CI: −1.42 to −0.95, p < 0.00001). Eleven studies indicated that TEAS decreased the incidence of PONV (RR = 0.47.95% CI:0.37~0.61, P<0.00001). Four studies were included in the meta-analysis of postoperative nausea, showing a significant reduction in incidence in the TEAS group compared to controls (RR = 0.33, 95% CI: 0.22 to 0.49, p < 0.00001). Another four studies showed a downward trend in postoperative vomiting but without statistical significance (RR = 0.69, 95% CI: 0.44 to 1.09, p = 0.11).
ConclusionTEAS appears to be an effective adjunctive intervention for alleviating postoperative pain and nausea in patients undergoing cancer surgery, showing clear clinical advantages. Further high-quality, large-scale, and multicenter studies are warranted to confirm its long-term efficacy and to promote the standardization of TEAS protocols for broader clinical application.
Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251038890